Home›Lopinavir And Ritonavir›Lopinavir And Ritonavir + Lamotrigine Extended Release

Does Lopinavir And Ritonavir Interact with Lamotrigine Extended Release?

CDI records a moderate classification for Lopinavir And Ritonavir and Lamotrigine Extended Release. The stored summary is: Decreases lamotrigine concentration approximately 50%. The mechanism involves induces lamotrigine glucuronidation via cyp3a4. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity: Moderate
Lopinavir And Ritonavir Class: Protease Inhibitor
Lamotrigine Extended Release Class: Anti-epileptic Agent
Management: Monitor for effects
Data Source: U.S. FDA via OpenFDA

Recorded Mechanism

Induces lamotrigine glucuronidation via CYP3A4

What To Tell Your Doctor or Pharmacist

If you are taking Lopinavir And Ritonavir and your doctor is considering prescribing Lamotrigine Extended Release (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask whether any dosage adjustments are needed
Never stop or change either medication without first consulting your healthcare provider

💊 Lopinavir And Ritonavir(Kaletra)+💊 Lamotrigine Extended Release(Lamotrigine)

Severity & Interaction Details

🟡

moderate

Be aware — moderate interaction

Documented interaction with manageable risk. May require dose adjustment or monitoring.

Severity scale

MinorContra

On record

Yes

Drug A class

Protease Inhibitor

Drug B class

Anti-epileptic Agent

Source

NLP:lamotrigine er

What this means in plain English

Decreases lamotrigine concentration approximately 50%.

About Lopinavir And Ritonavir and Lamotrigine Extended Release

Lopinavir And Ritonavir is a Protease Inhibitor, while Lamotrigine Extended Release is an Anti-epileptic Agent. Lopinavir And Ritonavir is also sold under the brand name Kaletra. Lamotrigine Extended Release additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:lamotrigine er

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Lopinavir And Ritonavir and Lamotrigine Extended Release against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.